CXCL13 and myeloid sarcoma: Neurofilaments intermediate, fetuin A, CXCL13, and osteopontin were associated with therapeutic response, suggesting they can contribute in the assessment of therapy effectiveness.28 Therefore, it is possible that in the near future these new CSF biomarkers will contribute to the clinical monitoring of MS patients.